Healio

Repeated injections of relabotulinumtoxinA safe long term for frown lines, crow’s feet

Please provide your email address to receive an email when new articles are posted on . 43.9% of patients experienced a treatment-emergent adverse event. Only 18.2% were treatment related. Efficacy ...
Nasdaq

Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic ...

- Results suggest that the extended duration of therapeutic benefit with DaxibotulinumtoxinA for Injection can produce dermal remodeling due to the prolonged period of muscle inactivity “The data ...
Benzinga.com

Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines

The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of ...
Business Insider

Brand Institute Partners on Brand Name and Nonproprietary Name Development for FDA Approved Injection for Frown Lines

MIAMI, Sept. 12, 2022 /PRNewswire/ -- Brand Institute is proud to announce its work with Revance Therapeutics in developing the brand name DAXXIFY™, which was approved by the FDA on September 7, 2022.
Business Wire

Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic ...

Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating ...